FTC Order Blocks Fresenius’ Ability To Inflate Medicare Venofer
Executive Summary
The Federal Trade Commission is offering to set aside concerns with a Venofer licensing deal between Fresenius and Daiichi Sankyo if Fresenius continues to report a product price to Medicare that is no higher than the current market price